Literature DB >> 3486822

The effects of interleukins and other soluble factors on T-lymphocyte colony formation.

A Winkelstein, P L Simon, D Wood, L L Machen, R K Shadduck, A Waheed.   

Abstract

When plated in semi-solid media, PHA-stimulated human peripheral blood mononuclear cells (PBMC) form discrete T-cell colonies. By contrast, Sephadex G-10 non-adherent (NA) cells (greater than 96% T lymphocytes) show virtually no clonal growth unless cocultured with soluble factors derived from either normal adherent cells or tumour cell lines. Purified IL-1 was able to initiate colony growth of mitogen-stimulated NA cells; cultures containing 20 U of human IL-1 yielded colony counts that were only slightly less than those with PBMC. In addition, recombinant IL-2, free of measurable IL-1, was able to provide the initiating signal required for clonal expansion. Both recombinant and lymphocyte-derived IL-2 were able to enhance the clonal growth of PBMC. Colony growth could be initiated by supernatants derived from short-term cultures of either monocytic (U937, HL60) or B-cell (Raji, Daudi) tumour cell lines. The abilities of these tumour cell lines to promote clonal responses did not correlate with their contents of either IL-1 or IL-2. By contrast, supernatants derived from either K562 (an erythroleukaemic line) or MOLT 4 (a T-cell lymphoma) cells did not provide the initiating signal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486822      PMCID: PMC1452656     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  Effect of human leukocyte interferon on the response of lymphocytes to mitogenic stimuli in vitro.

Authors:  H Blomgren; H Strander; K Cantell
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

2.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

3.  Reduced T lymphoid colony growth in patients with progressive systemic sclerosis and rheumatoid arthritis.

Authors:  A Winkelstein; M L Bernstein; M A Stevens; G P Rodnan; T A Medsger; S A Dobson
Journal:  J Lab Clin Med       Date:  1982-08

4.  Purification of colony-stimulating factor by affinity chromatography.

Authors:  A Waheed; R K Shadduck
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

5.  Leukemia-derived growth factor (non-interleukin 2) produced by a human malignant T lymphoid cell line.

Authors:  C H Uittenbogaart; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  Dependency of human T lymphocyte colony formation on soluble factors produced by accessory or tumor cells.

Authors:  A Winkelstein
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  The role of interleukin 1 and interleukin 2 in human T colony formation.

Authors:  B Klein; A Rey; M Jourdan; B Serrou
Journal:  Cell Immunol       Date:  1983-04-15       Impact factor: 4.868

8.  Biochemical heterogeneity of human interleukin-1.

Authors:  E J Ihrie; D D Wood
Journal:  Lymphokine Res       Date:  1985

Review 9.  Interleukin 2: biology and biochemistry.

Authors:  S Gillis
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

10.  The role of subcellular factors in pulmonary immune function: physicochemical characterization of two distinct species of lymphocyte-activating factor produced by rabbit alveolar macrophages.

Authors:  P L Simon; W F Willoughby
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

View more
  1 in total

1.  Defective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection.

Authors:  A Winkelstein; L A Kingsley; R S Klein; D W Lyter; T L Evans; C R Rinaldo; L D Weaver; L L Machen; R C Schadle
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.